Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9517219 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(10 years from now) | |
US9161926 | ALMIRALL | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
Nov, 2033
(10 years from now) | |
US11273132 | ALMIRALL | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Nov, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Sep 10, 2022 |
Market Authorisation Date: 24 February, 2016
Treatment: Topical treatment of acne vulgaris
Dosage: GEL;TOPICAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic